Jeongyoung Hwang

Jeongyoung Hwang

Auto-generated profile, based on publicly available information

Jeongyoung Hwang

AI Graduated School, Gwangju Institute of Science and Technology, Gwangju, South Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SMSehwan Moon
Sehwan Moon
YLYoungsuk Lee
Youngsuk Lee
JHJeongyoung Hwang
Jeongyoung Hwang
CKChul Gu Kim
Chul Gu Kim
JKJong Woo Kim
Jong Woo Kim
JKJae Hui Kim
Jae Hui Kim
To develop an artificial intelligence (AI) model that predicts anti-vascular endothelial growth factor (VEGF) agent-specific anatomical treatment outcomes in neovascular age-related macular degeneration (AMD), thereby assisting clinicians in selecting the most suitable anti-VEGF agent for each patient. This retrospective study included patients diagnosed with neovascular AMD who received three loading injections of either ranibizumab or aflibercept. Training was performed using optical coherence tomography (OCT) images with an attention generative adversarial network (GAN) model. To test the performance of the AI model, the sensitivity and specificity to predict the presence of retinal fluid after treatment were calculated for the AI model, an experienced (Examiner 1), and a less experienced (Examiner 2) human examiners. A total of 1684 OCT images from 842 patients (419 treated with ranibizumab and 423 treated with aflibercept) were used as the training set. Testing was performed using images from 98 patients. In patients treated with ranibizumab, the sensitivity and specificity, respectively, were 0.615 and 0.667 for the AI model, 0.385 and 0.861 for Examiner 1, and 0.231 and 0.806 for Examiner 2. In patients treated with aflibercept, the sensitivity and specificity, respectively, were 0.857 and 0.881 for the AI model, 0.429 and 0.976 for Examiner 1, and 0.429 and 0.857 for Examiner 2. In 18.5% of cases, the fluid status of synthetic posttreatment images differed between ranibizumab and aflibercept. The AI model using GAN might predict anti-VEGF agent-specific short-term treatment outcomes with relatively higher sensitivity than human examiners. Additionally, there was a difference in the efficacy in fluid resolution between the anti-VEGF agents. These results suggest the potential of AI in personalized medicine for patients with neovascular AMD.

10 November 2022 in IEEE Access
Verified
Journal Article
Open access
JHJeongyoung Hwang
Jeongyoung Hwang
HLHyunju Lee
Hyunju Lee
Integration of multiple biological datasets is crucial to understand comprehensive biological mechanisms with the aid of a rapid development of biomedical technology. However, the predictive modeling for such an integrated dataset faces two major challenges, namely, heterogeneity and imbalance in the acquired data. Thus, in this study, we present a method for the integration of multiple biological datasets called multimodal multitask matrix factorization (MMMF) to address these issues. The MMMF uses matrix factorization (MF) to integrate data from multiple heterogeneous biological datasets, and oversampling is applied to resolve the imbalanced data during the training step. Moreover, gradient surgery is used for multitask (MF and classification) learning to increase the quantity of classification information by projecting the gradients of the MF that conflict with the classification gradient onto the normal plane of a classification gradient. We demonstrate that MMMF outperforms other state-of-the-art biomedical classification models in binary and multi-class classification problems using five biological datasets. We also show that MMMF can be used as a feature selection approach for finding biomarkers that help in classification. The source code of the MMMF is available at https://github.com/DMCB-GIST/MMMF.